Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCYNERGIA: Ibrexafungerp plus voriconazole for invasive pulmonary aspergillosis
2018-002565-18Phase 2Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Jun 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Acute Invasive Aspergillosis and pulmonary aspergillosis comparing Ibrexafungerp + voriconazole with Placebo + voriconazole (2 arms). Primary endpoint: Primary: Safety and tolerability. Started Jun 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
Acute Invasive Aspergillosispulmonary aspergillosis
Beyond the preview
Go deeper on 2018-002565-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002565-18.